Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $588.99 million for fiscal year 2025.
CATALYST PHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $588.99M | +19.8% |
| 2024 | $491.73M | +23.5% |
| 2023 | $398.20M | +85.9% |
| 2022 | $214.20M | +52.1% |
| 2021 | $140.83M | +18.3% |
| 2020 | $119.07M | +16.4% |
| 2019 | $102.31M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $148.39M | +15.3% | +1.2% |
| June 30, 2025 | $146.56M | +19.4% | +3.6% |
| March 31, 2025 | $141.42M | +43.6% | +9.9% |
| September 30, 2024 | $128.69M | +25.3% | +4.9% |
| June 30, 2024 | $122.71M | +23.2% | +24.6% |
| March 31, 2024 | $98.51M | +15.4% | -4.1% |
| September 30, 2023 | $102.69M | +79.4% | +3.1% |
| June 30, 2023 | $99.58M | +87.5% | +16.7% |
- CATALYST PHARMACEUTICALS, INC. showed an increase of +19.8% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2019–2025 period, CATALYST PHARMACEUTICALS, INC.’s revenue (asc 606) has grown by 475.7% (from $102.31 million to $588.99 million).
- The most recent figure is from CATALYST PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: